oligoDOM® is a breakthrough cost-effective technology developed
- Internally, at Osivax, in two indications: Flu and Immuno-oncology
- In collaboration with public partners in other infectious diseases. The two most advanced programs are in Malaria with the Jenner Institute in the UK and Human Papilloma Virus (HPV) with the DKFZ in Germany
